Miguel A Frias

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/901782/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Sphingosineâ€1â€phosphate as a key player of insulin secretion induced by highâ€density lipoprotein treatment. Physiological Reports, 2021, 9, e14786.	1.7	1
2	High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases. Metabolism: Clinical and Experimental, 2020, 104, 154141.	3.4	11
3	HIV-related cardiovascular disease: any role for high-density lipoproteins?. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H1221-H1226.	3.2	6
4	Auto-antibodies against apolipoprotein A-1 block cancer cells proliferation and induce apoptosis. Oncotarget, 2020, 11, 4266-4280.	1.8	0
5	HDL protects against myocardial ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3. PLoS ONE, 2019, 14, e0218432.	2.5	18
6	ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1. Journal of Immunological Methods, 2019, 469, 33-41.	1.4	5
7	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. Journal of Clinical Medicine, 2019, 8, 2035.	2.4	10
8	Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?. Current Pharmaceutical Design, 2019, 25, 3128-3146.	1.9	10
9	Highâ€density lipoprotein from endâ€stage renal disease patients exhibits superior cardioprotection and increase in sphingosineâ€1â€phosphate. European Journal of Clinical Investigation, 2018, 48, e12866.	3.4	16
10	Impact of long distance rowing on biological health: A pilot study. Clinical Biochemistry, 2018, 52, 142-147.	1.9	7
11	Highâ€density lipoproteinâ€associated sphingosineâ€1â€phosphate activity in heterozygous familial hypercholesterolaemia. European Journal of Clinical Investigation, 2017, 47, 38-43.	3.4	3
12	Pharmacological Intervention to Modulate HDL: What Do We Target?. Frontiers in Pharmacology, 2017, 8, 989.	3.5	47
13	Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution. Lipids in Health and Disease, 2016, 15, 92.	3.0	47
14	Abca1 deficiency protects the heart against myocardial infarction-induced injury. Atherosclerosis, 2016, 251, 159-163.	0.8	8
15	Sphingosine-1-phosphate reduces ischaemia–reperfusion injury by phosphorylating the gap junction protein Connexin43. Cardiovascular Research, 2016, 109, 385-396.	3.8	55
16	Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 817-824.	2.4	61
17	CD14 as a Mediator of the Mineralocorticoid Receptor–Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes. Endocrinology, 2015, 156, 4707-4719.	2.8	20
18	Improving Reconstituted HDL Composition for Efficient Post-Ischemic Reduction of Ischemia Reperfusion Injury. PLoS ONE, 2015, 10, e0119664.	2.5	40

MIGUEL A FRIAS

#	Article	IF	CITATIONS
19	Therapeutic Potential of HDL in Cardioprotection and Tissue Repair. Handbook of Experimental Pharmacology, 2015, 224, 527-565.	1.8	39
20	High Density Lipoproteins and Ischemia Reperfusion Injury: The Therapeutic Potential of HDL to Modulate Cell Survival Pathways. Advances in Experimental Medicine and Biology, 2014, 824, 19-26.	1.6	4
21	HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity. Atherosclerosis, 2013, 228, 110-116.	0.8	42
22	JAK-STAT signaling and myocardial glucose metabolism. Jak-stat, 2013, 2, e26458.	2.2	18
23	High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection. Jak-stat, 2012, 1, 92-100.	2.2	24
24	HDLs Protect Pancreatic β-Cells Against ER Stress by Restoring Protein Folding and Trafficking. Diabetes, 2012, 61, 1100-1111.	0.6	63
25	The natural cardioprotective particle HDL modulates connexin43 gap junction channels. Cardiovascular Research, 2012, 93, 41-49.	3.8	37
26	Interplay Between SAFE and RISK Pathways in Sphingosine-1-Phosphate–Induced Cardioprotection. Cardiovascular Drugs and Therapy, 2012, 26, 227-237.	2.6	77
27	Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovascular Research, 2010, 85, 118-126.	3.8	67
28	Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: Role of sphingosine-1-phosphate. Cardiovascular Research, 2009, 82, 313-323.	3.8	90
29	The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis. Cardiovascular Research, 2008, 80, 69-77.	3.8	28
30	Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. Cardiovascular Research, 2007, 73, 57-65.	3.8	66
31	Prostacyclin production in rat aortic smooth muscle cells: role of protein kinase C, phospholipase D and cyclooxygenase-2 expression. Cardiovascular Research, 2003, 60, 438-446.	3.8	5